Australie - anglais - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - 44904 - blood/tissue storage/culture container - sterile plastic bags with in-line leukocyte filter provides a closed system for the storage and separation of whole blood or its components.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - imipramine hydrochloride -

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - fentanyl citrate 78.5 µg/ml equivalent to 50 µg/ml fentanyl - solution for injection - 50 mcg/ml - active: fentanyl citrate 78.5 µg/ml equivalent to 50 µg/ml fentanyl excipient: sodium chloride sodium hydroxide water for injection - fentanyl injection is indicated for: · analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; · use as a narcotic analgesic supplement in general and regional anaesthesia; · administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.05mg (anhydrous) - tablet - 0.05 mg - active: levothyroxine sodium 0.05mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.1mg (anhydrous) - tablet - 0.1 mg - active: levothyroxine sodium 0.1mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - hydrochlorothiazide 12.5mg; losartan potassium 50mg - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg excipient: hypromellose lactose monohydrate macrogol 4000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc quinoline yellow titanium dioxide - losartan hctad is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate - solution for infusion - 15 mg/5ml - active: pamidronic acid 12.63mg equivalent to 15 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate - solution for infusion - 30 mg/10ml - active: pamidronic acid 25.27mg equivalent to 30 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 50.54mg equivalent to 60 mg disodium pamidronate - solution for infusion - 60 mg/10ml - active: pamidronic acid 50.54mg equivalent to 60 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - pamidronic acid 75.82mg equivalent to 90 mg disodium pamidronate - solution for infusion - 90 mg/10ml - active: pamidronic acid 75.82mg equivalent to 90 mg disodium pamidronate excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominantly lytic bone metastases from breast cancer and advanced multiple myeloma